American Association for Cancer Research
mct-23-0267_supplementary_figures_1_and_2_suppsf1-2.pdf (297.15 kB)

Supplementary Figures 1 and 2 from Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource

Download (297.15 kB)
journal contribution
posted on 2023-11-01, 08:02 authored by Joel Morris, Mark W. Kunkel, Stephen L. White, Donn G. Wishka, Omar D. Lopez, Lori Bowles, Penny Sellers Brady, Patricia Ramsey, Julie Grams, Tiffany Rohrer, Karen Martin, Thomas S. Dexheimer, Nathan P. Coussens, David Evans, Prabhakar Risbood, Dmitriy Sonkin, John D. Williams, Eric C. Polley, Jerry M. Collins, James H. Doroshow, Beverly A. Teicher

Figures S1 and S2





The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public ( and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.

Usage metrics

    Molecular Cancer Therapeutics